Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text

Medicine, Oncology, Pharmacology +13

World Health Organization Classification of Tumours

CDM Fletcher, Anke van den Berg, Ineke Molenaar · 2002 · 7.1K citations

Medicine, Oncology, Pathology +11

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al. · New England Journal of Medicine · 2010 · 5.6K citations

Medicine, Oncology, Pharmacology +13

ras oncogenes in human cancer: a review.

Joyce Bos · PubMed · 1989 · 5.1K citations

Medicine, Genetics, Oncology +17

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao, Vincent A. Miller, Maureen F. Zakowski et al. · Proceedings of the National Academy of Sciences · 2004 · 4.3K citations · Full text

Medicine, Molecular Genetics, Oncology +16